

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number  
**WO 2006/064228 A2**

(51) International Patent Classification:  
*C07D 513/04* (2006.01) *A61P 29/02* (2006.01)  
*A61K 31/519* (2006.01)

**STONEHOUSE, Jeffrey, Paul** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

(21) International Application Number:  
PCT/GB2005/004825

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:  
14 December 2005 (14.12.2005)

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0427698.6 17 December 2004 (17.12.2004) GB  
0502542.4 8 February 2005 (08.02.2005) GB

(71) Applicant (*for all designated States except MG, US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for MG only*): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **MEGHANI, Premji** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **CHESHIRE, David, Ranulf** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **PRESTON, Cherylin, Francis** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB).

Published:

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS



(57) Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof; and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

WO 2006/064228 A2

## COMPOUNDS

The present invention relates to certain heterocyclic compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved cysteine motif. At the present time, the chemokine superfamily comprises four groups exhibiting characteristic structural motifs, the C-X-C, C-C and C-X<sub>3</sub>-C and XC families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X<sub>3</sub>-C family is distinguished from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues. In contrast, members of the XC family lack one of the first two cysteine residues.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 $\alpha$  and 1 $\beta$  (MIP-1 $\alpha$  and MIP-1 $\beta$ ).

The C-X<sub>3</sub>-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.

Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family. These receptors represent

good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

In accordance with the present invention, there is therefore provided a compound of general formula (I)



wherein

$R^1$  is a group selected from  $C_{3-7}$ carbocyclyl,  $C_{1-8}$ alkyl,  $C_{2-6}$ alkenyl and  $C_{2-6}$ alkynyl; wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, nitrile,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ , phenyl or heteroaryl; wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_{1-6}$ alkyl and trifluoromethyl;

X is  $-CH_2-$ , a bond, oxygen, sulphur, sulfoxide, or sulphone;

Z is  $-CH_2-$ , a bond, oxygen, sulphur, sulfoxide, sulphone or  $-NR^5$ ;

$R^2$  is  $C_{3-7}$ carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently selected from fluoro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ;

or  $R^2$  is a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S,  $-NR^8$  and whereby the ring is optionally substituted by 1, 2 or 3 substituents independently selected from  $C_{1-3}$ alkyl, fluoro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ;


or  $R^2$  is phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3

substituents independently selected from halo, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-NR^8COR^9$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_{1-6}$ alkyl and trifluoromethyl;

or  $R^2$  is a group selected from  $C_{1-8}$ alkyl,  $C_{2-6}$ alkenyl or  $C_{2-6}$ alkynyl wherein the group is substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylamino, di( $C_{1-6}$ alkyl)amino,  $N$ -( $C_{1-6}$ alkyl)- $N$ -(phenyl)amino,  $N$ - $C_{1-6}$ alkylcarbonyl,  $N,N$ -di( $C_{1-6}$ alkyl)carbonyl,  $N$ -( $C_{1-6}$ alkyl)- $N$ -(phenyl)carbonyl, carboxy, phenoxycarbonyl,  $-NR^8COR^9$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$  and  $-CONR^5R^6$ ;

$Y$  is selected from hydrogen, hydroxyl, halo,  $-NR^3R^4$ , and  $-NR^8SO_2R^9$ ;

$R^3$  and  $R^4$  each independently represent a hydrogen atom, or a 4-piperidinyl group, or  $R^3$  and  $R^4$  each independently represent a  $C_3$ - $C_6$  cycloalkyl or  $C_1$ - $C_8$  alkyl group, which groups may be optionally substituted by 1, 2 or 3 substituent groups independently selected from halo,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-OR^7$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ , morpholinyl,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl, tetrahydrofuranyl and aryl, wherein an aryl group may be optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-OR^7$ ,  $-NR^8COR^9$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_1$ - $C_6$  alkyl and trifluoromethyl, or  $R^3$  and  $R^4$  together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally substituted by one or more substituent groups independently selected from



$-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-OR^7$ ,  $-COOR^{10}$ ,  $-NR^8COR^9$ , and  $C_1$ - $C_6$  alkyl optionally substituted by 1, 2 or 3 substituents independently selected from halogen atoms and  $-NR^{11}R^{12}$  and  $-OR^7$  groups;

$R^5$  and  $R^6$  are independently selected from hydrogen or a group selected from  $C_{1-6}$ alkyl and phenyl wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl,  $-OR^{14}$ ,  $-NR^{15}R^{16}$ ,  $-COOR^{14}$ ,  $-CONR^{15}R^{16}$ ,  $-NR^{15}COR^{16}$ ,  $-SO_2R^{10}$ ,  $-SONR^{15}R^{16}$  and  $NR^{15}SO_2R^{16}$

$R^7$  and  $R^9$  each independently represent a hydrogen atom or a  $C_1$ - $C_6$ , particularly  $C_1$ - $C_4$ , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group, each of which may be optionally substituted by one or more (e.g. one, two, three or four) substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl,  $-OR^{17}$  and  $-NR^{15}R^{16}$ ; and each of  $R^8$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{15}$ ,  $R^{16}$  and  $R^{17}$  independently represents a hydrogen atom or a  $C_1$ - $C_6$ , particularly  $C_1$ - $C_4$ , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group or a pharmaceutically acceptable salt or solvate thereof.

Convenient values of  $R^1$ ,  $R^2$ , X, Z and Y are as follows. Such values may be used independently where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

$R^1$  is  $C_{1-8}$ alkyl optionally substituted by 1, 2 or 3 substituents independently selected from nitrile, phenyl or heteroaryl, wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano,  $-OR^4$ ,  $-SR^{10}$ ,  $C_{1-6}$ alkyl and trifluoromethyl wherein  $R^4$  and  $R^{10}$  are as defined in formula (I); or

$R^1$  is  $C_{1-4}$ alkyl optionally substituted by 1, 2 or 3 substituents independently selected from phenyl or heteroaryl, wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano,  $-OR^4$ , and trifluoromethyl wherein  $R^4$  is as defined in formula (I); or

$R^1$  is  $C_{1-4}$ alkyl substituted by phenyl optionally substituted by 1, 2, or 3 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl; or

$R^1$  is  $C_{1-2}$ alkyl substituted by phenyl optionally substituted by 1, 2, or 3 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl.

$R^2$  is  $C_{1-8}$ alkyl substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkylamino, carboxy,  $-NR^8COR^9$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$  and  $-CONR^5R^6$ , wherein  $R^5$ ,  $R^6$ ,  $R^8$ ,  $R^9$  and  $R^{10}$  are as defined in formula (I);

or

$R^2$  is  $C_{1-8}$ alkyl substituted with 1 or 2 hydroxy groups, carboxy,  $-NR^8COR^9$  or  $-CONR^5R^6$ ; wherein  $R^5$ ,  $R^6$ ,  $R^8$  and  $R^9$  are as defined in formula (I); or

$R^2$  is  $C_{1-4}$ alkyl substituted with 1 or 2 hydroxy groups, carboxy,  $-NHCOC_{1-4}$ alkyl or  $-CONR^5R^6$  wherein  $R^5$  and  $R^6$  are either hydrogen or  $C_{1-4}$ alkyl; or

5  $R^2$  is  $C_{1-4}$ alkyl substituted with 1 or 2 hydroxy groups.

It will be appreciated that when  $R^2$  is a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S,  $-NR^8$  then such ring is linked via a carbon ring atom (ie. it is not linked to X via the optional heteroatom).

X is a bond,  $-CH_2-$ , oxygen, or sulphur; or X is a bond or oxygen

10 In a further aspect of the present invention there is provided a compound of formula (1) as depicted above in which Z is a bond,  $-CH_2-$ , oxygen, sulphur or  $NR^5$ .

In another aspect of the invention Z is a bond,  $-CH_2-$ , oxygen or sulphur.

In another aspect of the invention Z is a bond,  $-CH_2-$  or sulphur

In another aspect of the invention Z is a bond or sulphur

15 In a further aspect of the present invention there is provided a compound of formula (I) as depicted above wherein Y is a hydrogen atom, or a group hydroxyl,  $-NR^3R^4$  or  $-NR^8SO_2R^9$  wherein  $R^3$ ,  $R^4$ ,  $R^8$  and  $R^9$  are as defined in formula (I).

In another aspect of the invention Y is hydroxyl,  $-NR^3R^4$  or  $-NR^8SO_2R^9$  wherein  $R^3$ ,  $R^4$ ,  $R^8$  and  $R^9$  are as defined in formula (I).

20 In another aspect of the invention Y is hydroxyl,  $-NR^3R^4$  or  $-NR^8SO_2R^9$  wherein  $R^3$ ,  $R^4$ ,  $R^8$  are either hydrogen or  $C_{1-4}$ alkyl and  $R^9$  is either  $C_{1-4}$ alkyl or trifloromethyl.

In another aspect of the invention Y is hydroxyl,  $-NH_2$  or  $-NHSO_2Me$ .

Particular compounds of the invention include:

25 3-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-propanoic acid,

3-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-propanamide,

N-[2-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]ethyl]- acetamide,

1-propanol, 2-[[2-amino-5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, (2*R*)-,

(2*R*)-2-({2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy)propan-1-ol, and


5 (2*S*)-2-({2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy)propan-1-ol

5-[(2,3-difluorobenzyl)thio]-7-[(1*R*)-2-hydroxy-1-methylethoxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

Each of the above mentioned compounds and the pharmaceutically acceptable salts,  
10 solvates or *in vivo* hydrolysable esters thereof, taken individually is a preferred aspect of the invention.

According to the invention there is also provided a process for the preparation of a compound of formula (I) which comprises:

When X represents -O- or -S-, and Z, R<sup>1</sup> and Y are as defined in formula (I), with  
15 the proviso that Y is not hydroxyl, reacting a compound of general formula (II)




with a suitable alkylhalide (R<sup>2</sup>-L) wherein R<sup>2</sup> is as defined in formula (I) and L is a leaving group such as halogen, alkyl- or aryl- sulphonate or activated alcohol under standard Mitsunobu reaction conditions (Synthesis 1, 1981) using trialkyl- or triaryl- phosphine and  
20 dialkylazidodicarboxylate in the presence of a suitable base and solvent. Examples of suitable bases include trialkylamines, such as triethylamine or *N,N*-diisopropylethylamine, pyridine or 4-dimethylaminopyridine or alkali metal hydroxides such as Li, Na, or K, or metal carbonates such as Li, Na, K or Cs, or metal acetates such as Li, Na, K or Cs, or metal alkoxides such as Li, Na, K-*tert*-butoxide. Preferably triethylamine or *N,N*-  
25 diisopropylethylamine is used. Suitable trialkyl- or triaryl- phosphines include tri-*n*-butylphosphine or triphenylphosphine. Suitable dialkylazidodicarboxylates include diethylazidodicarboxylate or diisopropylazidodicarboxylate. Suitable solvents include dichloromethane, pyridine, *N,N*-dimethylamides, 1-methyl-2-pyrrolidone, and ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme. Preferably *N,N*-dimethylformamide

or tetrahydrofuran is used. The temperature of the reaction can be performed between 0°C and 120°C.

Compounds of Formula (II) may be prepared as described in our published PCT patent application WO0009511 (AstraZeneca).

- 5 According to the invention there is also provided a process for the preparation of a compound of formula (I), wherein Y is hydroxyl, or a pharmaceutically acceptable salt or solvate thereof, which process comprises reacting a compound of general formula (III); wherein L is a leaving group and PG is a suitable protecting group




- 10 with suitable nucleophiles (e.g.  $\text{HX-R}^2$ ,  $(\text{Metal})\text{X-R}^2$ ,  $\text{Mg}(\text{Halogen})\text{X-R}^2$ ) wherein  $\text{R}^2$  is as defined in formula (I) in the presence or absence of a suitable base and solvent. Preferably L is a halogen. Examples of suitable protecting groups include tetrahydropyranyl, trimethylsilylethoxymethyl, phenyloxymethyl, methyloxymethyl, benzyloxymethyl, phenylethylsulfone and propionitrile. Preferably tetrahydropyranyl is used. Examples of
- 15 suitable bases include trialkylamines, such as triethylamine or *N,N*-diisopropylethylamine, pyridine or 4-dimethylaminopyridine or alkali metal hydrides such as Li, Na, or K or alkali metal hydroxides such as Li, Na, or K, or metal carbonates such as Li, Na, K or Cs, or metal acetates such as Li, Na, K or Cs, or metal alkoxides such as Li, Na, K *tert*-butoxide. Preferably sodium hydride is used. Suitable solvents include dichloromethane, pyridine,
- 20 *N,N*-dimethylamides, 1-methyl-2-pyrrolidinone, and ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme. Preferably *N,N*-dimethylformamide or tetrahydrofuran is used. Examples of suitable metals are Li, Na, K, Zn, Ce, Cu, Sn, and Pd. The temperature of the reaction can be performed between 0°C and 120°C.


- 25 Compounds of formula (I), wherein X and/or Z are sulfoxide or sulphone and  $\text{R}^1$  and  $\text{R}^2$  are as defined hereinbefore, may be prepared by further reaction of compounds of formula (I), wherein X and/or Z are sulphur, with a suitable oxidising reagent. Examples of suitable oxidising reagents include, hydrogen peroxide, sodium periodate, periodic acid, peroxy acids such as metachloroperbenzoic acid and peracetic acid and oxone.



Compounds of Formula (III), wherein Y is hydroxyl and R<sup>1</sup>, Z, L and PG are as described hereinbefore, may be prepared from compounds of formula (IV) wherein R<sup>1</sup> and Z are as defined in formula (I) and L is a halogen by reaction with a suitable protecting group reagent under appropriate reaction conditions as is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2<sup>nd</sup> Edition, T. W. Greene & P. G. M. Wuts, Wiley Interscience (1991).




Compounds of Formula (IV), wherein Y is hydroxyl and R<sup>1</sup>, Z, and L are as defined hereinbefore may be prepared from compounds of formula (V) wherein R<sup>1</sup> and Z are as defined in formula (I)



by treatment with phosphorous oxychloride in the presence of a phase transfer reagent and suitable solvent. Examples of phase transfer reagents include tetraalkylammonium halides and tetraalkylphosphonium halides. Preferably benzyltrimethylammonium chloride is used. Suitable solvents include acetonitrile, toluene, xylene, *N,N*-dimethylaniline, *N,N*-diethylaniline, 1,2-dimethoxyethane and ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme. Preferably a mixture of acetonitrile and *N,N*-diethylaniline is used. The reaction can be performed between temperatures of 30°C and 120°C.

Compounds of formula (V), wherein Y is hydroxyl and R<sup>1</sup> and Z are as defined hereinbefore, may be prepared from compounds of formula (VI), wherein R<sup>1</sup> and Z are as defined in formula (I)



by treatment with a halocarbonylsulfonyl halide in the presence of suitable solvent.


Convenient halogen atoms are independently selected from chlorine and bromine.

Preferably chlorine as the halogen atom is used, and chlorocarbonylsulfonyl chloride is

therefore the preferred reagent. Examples of suitable solvents include dichloromethane, and ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, glyme, diglyme and diethylether. Tetrahydrofuran and diethylether are preferred. The reaction can be performed between temperatures of 0°C and 50°C.

Compounds of formula (VI), wherein Y is hydroxyl and Z represents -O- or -S-

and R<sup>1</sup> is as defined hereinbefore, may be prepared from a compound of formula (VII) by treatment with an alkyl halide (R<sup>1</sup>L), wherein R<sup>1</sup> is as defined in formula (I) and L is a leaving group such as halogen or alkyl- or aryl-sulfonate



in the presence of suitable base and solvent. Examples of suitable base include

trialkylamines, such as triethylamine or *N,N*-diisopropylethylamine, pyridine or 4-dimethylaminopyridine or alkali metal hydroxides such as Li, Na or K, or metal carbonates such as Li, Na, K or Cs, or metal alkoxides such as Li, Na, K or Cs, or metal acetates such as Li, Na, K, or Cs or metal alkoxides such as Li, Na, K *tert*-butoxide. Preferably sodium acetate or sodium hydroxide is used. Examples of suitable solvent include acetonitrile,

pyridine, *N,N*-dimethylamides, 2-methyl-1-pyrrolidone, and ethers such as tetrahydrofuran,

1, 4-dioxane, glyme and diglyme. Preferably *N,N*-dimethylformamide or acetonitrile is used. The reaction is performed at temperatures between 0°C and 120°C.

The compounds of formula (I) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates.

The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

Within the present invention it is to be understood that a compound of formula (1) or a salt, solvate or *in vivo* hydrolysable ester thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form and mixtures thereof and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

It is also to be understood that certain compounds of formula (1) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically

acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, tartrates, oxalates, methanesulphonates or *p*-toluenesulphonates. Pharmaceutically acceptable salts of the invention may also include basic addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently acidic to form such salts. Such salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a lithium, sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or an organic amine salt, for example a salt with methylamine, dimethylamine, trimethylamine, triethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. Other basic addition salts include aluminium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine.

The present invention further relates to an *in vivo* hydrolysable ester of a compound of formula (1). An *in vivo* hydrolysable ester of a compound of formula (1) which contains carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C<sub>1-6</sub>alkoxymethyl esters for example methoxymethyl, C<sub>1-6</sub>alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C<sub>3-8</sub>cycloalkoxycarbonyloxyC<sub>1-6</sub>alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C<sub>1-6</sub>alkoxycarbonyloxyethyl esters for example

1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and  $\alpha$ -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of  $\alpha$ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in-vivo* hydrolysable ester forming groups for hydroxy include C<sub>1-10</sub>alkanoyl, for example acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl, C<sub>1-10</sub>alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-(C<sub>1-4</sub>)alkylcarbamoyl and *N*-(di-(C<sub>1-4</sub>)alkylaminoethyl)-*N*-(C<sub>1-4</sub>)alkylcarbamoyl (to give carbamates); di-(C<sub>1-4</sub>)alkylaminoacetyl and carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C<sub>1-4</sub>)alkylaminomethyl and di-((C<sub>1-4</sub>)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting *in-vivo* hydrolysable esters include, for example, R<sup>A</sup>C(O)O(C<sub>1-6</sub>)alkyl-CO-, wherein R<sup>A</sup> is for example, benzyloxy-(C<sub>1-4</sub>)alkyl, or phenyl). Suitable substituents on a phenyl group in such esters include, for example, 4-(C<sub>1-4</sub>)piperazino-(C<sub>1-4</sub>)alkyl, piperazino-(C<sub>1-4</sub>)alkyl and morpholino-(C<sub>1-4</sub>)alkyl.

The compounds of formula (1) above may be converted to a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as discussed above. The salt is preferably a basic addition salt.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Where a substituent in an alkenyl group is a phenoxy group, the phenoxy group is not attached to an unsaturated carbon atom. A carbocyclic group is a saturated hydrocarbyl group that may be monocyclic or polycyclic (e.g. bicyclic). Similarly, a saturated heterocyclic ring system may be monocyclic or polycyclic (e.g. bicyclic).

In this specification the term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight chain version only and references to individual branched-chain alkyl groups such as *t*-butyl are specific for the branched chain version only. For example,

“C<sub>1-3</sub>alkyl” includes methyl, ethyl, propyl and isopropyl and examples of “C<sub>1-6</sub>alkyl” include the examples of “C<sub>1-3</sub>alkyl” and additionally t-butyl, pentyl, 2,3-dimethylpropyl, 3-methylbutyl and hexyl. Examples of “C<sub>1-8</sub>alkyl” include the examples of “C<sub>1-6</sub>alkyl” and additionally heptyl, 2,3-dimethylpentyl, 1-propylbutyl and octyl. An analogous convention applies to other terms, for example “C<sub>2-6</sub>alkenyl” includes vinyl, allyl, 1-propenyl, 2-butenyl, 3-butenyl, 3-methylbut-1-enyl, 1-pentenyl and 4-hexenyl and examples of “C<sub>2-6</sub>alkynyl” includes ethynyl, 1-propynyl, 3-butylnyl, 2-pentylnyl and 1-methylpent-2-ynyl.

“C<sub>3-7</sub>carbocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 3 to 7 carbon ring atoms wherein a -CH<sub>2</sub>- group can optionally be replaced by a -C(O)-. Suitable examples of “carbocyclyl” are cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cyclohexenyl, 4-oxocyclohex-1-yl and 3-oxocyclohept-5-en-1-yl.

The term “halo” refers to fluoro, chloro, bromo and iodo.

Examples of “C<sub>1-6</sub>alkoxy” include methoxy, ethoxy, propoxy, isopropoxy, butyloxy, pentyloxy, 1-ethylpropoxy and hexyloxy. Examples of “C<sub>1-6</sub>alkylamino” include methylamino, ethylamino, propylamino, butylamino and 2-methylpropylmino. Examples of “di(C<sub>1-6</sub>alkyl)amino” include dimethylamino, *N*-methyl-*N*-ethylamino, diethylamino, *N*-propyl-*N*-3-methylbutylamino. Examples of “*N*-(C<sub>1-6</sub>alkyl)-*N*-(phenyl)amino” include *N*-methyl-*N*-phenylamino, *N*-propyl-*N*-phenylamino and *N*-(2-methylbutyl)-*N*-phenylamino. Examples of “*N*-(C<sub>1-6</sub>alkyl)carbamoyl” are *N*-methylcarbamoyl, *N*-ethylcarbamoyl and *N*-(2-ethylbutyl)carbamoyl. Examples of “*N*-(C<sub>1-6</sub>alkyl)-*N*-(phenyl)carbamoyl” include *N*-methyl-*N*-phenylcarbamoyl, *N*-butyl-*N*-phenylcarbamoyl and *N*-(3-methylpentyl)-*N*-(phenyl)carbamoyl. Examples of “*N,N*-di(C<sub>1-6</sub>alkyl)carbamoyl” include *N,N*-dimethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl and *N*-propyl-*N*-(2-methylbutyl)carbamoyl. Examples of “C<sub>1-6</sub>alkylthio” include methylthio, ethylthio, propylthio, butylthio and 2-methylbutylthio.

“Heteroaryl” is a monocyclic or bicyclic aryl ring containing 5 to 10 ring atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen. Examples of heteroaryl include pyrrolyl, furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, benzfuranyl, benzthieno, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benztriazolyl, quinolinyl, isoquinolinyl and

naphthiridinyl. Conveniently heteroaryl is selected from imidazolyl, pyrazolyl, thiazolyl, isoxazolyl, furanyl, thienyl, isoxazolyl, or indazolyl. Fully saturated heterocyclic rings include examples such as oxetanyl, azetidiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl and  
5 homopiperazinyl and tetrahydropyridinyl.

Examples of "a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S and NR<sup>8</sup>" include saturated rings such as oxetanyl, azetidiny, benzodiazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl,  
10 piperidinyl, piperazinyl, morpholinyl, homopiperidinyl and homopiperazinyl tetrahydrodioxanyl. Examples of "a 4- to 7-membered saturated heterocyclic ring system" include azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl and morpholinyl.

Where optional substituents are chosen from "1, 2 or 3" groups it is to be  
15 understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. An analogous convention applies to substituents chosen from "1 or 2" groups.

The compounds of formula (1) have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be used in the  
20 treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include (each taken independently):

(1) **the respiratory tract** - obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic,  
25 intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous  
30 rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;

- (2) **bone and joints** - rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behchet's disease, Sjogren's syndrome and systemic sclerosis;
- 5 (3) **skin** - psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermitides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
- 10 (4) **gastrointestinal tract** - Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, indeterminate colitis, microscopic colitis, inflammatory bowel disease, irritable bowel syndrome, non-inflammatory diarrhea, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- 15 (5) **central and peripheral nervous system** - Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic
- 20 inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man
- 25 syndrome: paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; and stroke.
- (6) **other tissues and systemic disease** - atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome,
- 30 eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia pupura; post-operative adhesions, and sepsis.



- (7) **allograft rejection** - acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- (8) **cancers** - especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma, and tumour metastasis, non melanoma skin cancer and chemoprevention metastases;
- (9) **diseases** - in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC, diabetic retinopathy);
- (10) **cystic fibrosis**;
- (11) **burn wounds & chronic skin ulcers**;
- (12) **reproductive diseases** – for example disorders of ovulation, menstruation and implantation, pre-term labour, endometriosis;
- (13) **re-perfusion injury** - in the heart, brain, peripheral limbs and other organs, inhibition of atherosclerosis.

Thus, the present invention provides a compound of formula (1), or a pharmaceutically-acceptable salt, solvate or an *in vivo* hydrolysable ester thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CXC chemokine receptor subfamily, more preferably the target chemokine receptor is the CXCR2 receptor.

Particular conditions which can be treated with the compounds of the invention are cancer, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels, and inflammatory diseases such as asthma, allergic rhinitis, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

As a further aspect of the present invention, the compounds of formula (1) may have utility as antagonists of the CX3CR1 receptor. Such compounds are expected to be particularly useful in the treatment of disorders within the central and peripheral nervous system and other conditions characterized by an activation of microglia and/or infiltration of leukocytes (e.g. stroke/ischemia and head trauma). In particular, the compounds are indicated for use in the treatment of neurodegenerative disorders or demyelinating disease in mammals including man. More particularly, the compounds are indicated for use in the treatment of multiple sclerosis. The compounds are also indicated to be useful in the

treatment of pain, rheumatoid arthritis, osteoarthritis, stroke, atherosclerosis and pulmonary arterial hypertension.

The compounds of the invention may also be used to treat diseases in which the chemokine receptor belongs to the CCR chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR2b receptor.

In a further aspect, the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament.

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament for the treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

In a further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating a chemokine mediated  
5 disease wherein the chemokine binds to a chemokine (especially CXCR2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula , or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester, as hereinbefore defined.

The invention also provides a method of treating an inflammatory disease,  
10 especially asthma, allergic rhinitis, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined.

15 For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compounds of formula (1) and pharmaceutically acceptable salts, solvates or *in vivo* hydrolysable esters thereof may be used on their own but will generally be  
20 administered in the form of a pharmaceutical composition in which formula (I) compound/salt/solvate/ester (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w,  
25 and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined, in association with a pharmaceutically  
30 acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (1), or a

pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier. The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compounds of the invention are administered orally.

In addition to their use as therapeutic medicines, the compounds of formula (I) and their pharmaceutically acceptable salts, solvate or *in vivo* hydrolysable esters are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effect of chemokine modulation activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

The invention further relates to combination therapies wherein a compound of formula (I) or a pharmaceutically acceptable salts, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of formula (I) is administered concurrently or sequentially with therapy and/or an agent for the treatment of any one of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis or osteoporosis.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, irritable bowel syndrome, COPD, asthma and allergic rhinitis the compounds of the invention may be combined with agents such as TNF- $\alpha$  inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and D.sub2.E.sub7.) and TNF receptor immunoglobulin molecules (such as Enbrel.reg.), non-selective COX-1 / COX-2 inhibitors (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) low dose methotrexate, lefunomide; ciclesonide;

hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold. For inflammatory bowel disease and irritable bowel disorder further convenient agents include sulphasalazine and 5-ASAs, topical and systemic steroids, immunomodulators and immunosuppressants, antibiotics, probiotics and anti-integrins.

5           The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as  
10   Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonist for leukotrienes LTB.sub4., LTC.sub4.,  
15   LTD.sub4., and LTE.sub4. selected from the group consisting of the phenothiazin-3-ones such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

20           The present invention still further relates to the combination of a compound of the invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

The present invention still further relates to the combination of a compound of the invention together with a antihistaminic H.sub1. receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and  
25   chlorpheniramine.

The present invention still further relates to the combination of a compound of the invention together with a gastroprotective H.sub2. receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with an  $\alpha$ .sub1.- and  $\alpha$ .sub2.-adrenoceptor agonist vasoconstrictor  
30   sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride,

tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents such as ipratropium bromide; tiotropium bromide; oxitropium bromide; pirzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the invention together with a  $\beta$ .sub1.- to  $\beta$ .sub4.-adrenoceptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

The present invention still further relates to the combination of a compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, such as prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-12.

The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX<sub>3</sub>CR1 for the C-X<sub>3</sub>-C family.

The present invention still further relates to the combination of a compound of the invention together with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antiseptic compounds such as Valant.

The present invention still further relates to the combination of a compound of the invention together with cardiovascular agents such as calcium channel blockers, lipid

lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

The present invention still further relates to the combination of a compound of the invention together with CNS agents such as antidepressants (such as sertraline), anti-  
5 Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

10 The present invention still further relates to the combination of a compound of the invention together with (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists; (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors; (v) adhesion molecule inhibitors including VLA-4 antagonists; (vi) cathepsins; (vii) MAP  
15 kinase inhibitors; (viii) glucose-6 phosphate dehydrogenase inhibitors; (ix) kinin-B.sub1. - and B.sub2. -receptor antagonists; (x) anti-gout agents, e.g., colchicine; (xi) xanthine oxidase inhibitors, e.g., allopurinol; (xii) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (xiii) growth hormone secretagogues; (xiv) transforming growth factor (TGF $\beta$ ); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (xvii) granulocyte  
20 macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) Tachykinin NK.sub1. and NK.sub3. receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) TNF  $\alpha$  converting enzyme inhibitors (TACE); (xxii) induced nitric oxide synthase inhibitors (iNOS) or (xxiii)  
25 chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and  
30 methotrexate;.

The compounds of the invention may also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in

combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc and P2X7 receptor antagonists.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel (Taxol®); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 $\alpha$ -reductase such as finasteride;
- (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erb2 antibody



trastuzumab [Herceptin™] and the anti-erbbl1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

- 10 (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin  
15  $\alpha v\beta 3$  function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;

- (vii) antisense therapies, for example those which are directed to the targets listed above,  
20 such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to

- 25 chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as  
30 cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

## **Pharmacological Data**

### **Ligand Binding Assay**

[<sup>125</sup>I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* 267 pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease inhibitors (1mM phenyl methyl sulphonyl fluoride, 2µg/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5µg/ml leupeptin and 100µg/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH<sub>2</sub>PO<sub>4</sub>), 0.1%(w/v) gelatin and 10%(v/v) glycerol.

All assays were performed in a 96-well MultiScreen 0.45µm filtration plates (Millipore, U.K.). Each assay contained ~50pM [<sup>125</sup>I]IL-8 and membranes (equivalent to ~200,000 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed

from the MultiScreen plate assembly, the filters dried at room temperature, punched out and then counted on a Cobra  $\gamma$ -counter.

The compounds of formula (I) according to the Examples 1 – 7 were found to have pIC<sub>50</sub> values of greater than (>) 4.5.

5

#### **Intracellular Calcium Mobilisation Assay**

Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) *Methods in Enzymology* 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH<sub>2</sub>PO<sub>4</sub>) supplemented with  
10 5.7mM glucose and 10mM HEPES (pH 7.4)].

The chemokine GRO $\alpha$  (human, recombinant) was purchased from R&D Systems (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990)  
15 *Biochem. J.* 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5 $\mu$ M fluo-3 AM ester, washed with loading buffer and then resuspended in Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM CaCl<sub>2</sub> and 1mM MgCl<sub>2</sub>. The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston,  
20 U.S.A.) and centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A<sub>50</sub> concentration of GRO $\alpha$  and the transient increase in fluo-3 fluorescence ( $\lambda_{Ex}$  = 490nm and  $\lambda_{Em}$  = 520nm) monitored using a FLIPR (Fluorometric  
25 Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

The compounds of formula (I) according to the Examples 1 – 4 were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

The invention will now be illustrated by the following non-limiting Examples  
30 in which, unless stated otherwise:

- (i) when given Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer. <sup>1</sup>H NMR data is quoted in

the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard.


(ii) Mass Spectrometry (MS) spectra were measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer.

5 (iii) the title and sub-titled compounds of the Examples and methods were named using the ACD/Name program (version 4.55) from Advanced Chemical Development Inc, Canada.

(iv) Normal phase column chromatography and normal phase HPLC was conducted using a silica column. Reverse phase High Pressure Liquid Chromatography (HPLC) purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000 or a Gilson Auto Purification System, using a Symmetry, NovaPak or Ex-Terra reverse phase silica column.

10 (v) The following abbreviations are used:

|    |                   |                               |
|----|-------------------|-------------------------------|
| 15 | AcOH              | acetic acid                   |
|    | CHCl <sub>3</sub> | chloroform                    |
|    | DCM               | dichloromethane               |
|    | DMF               | <i>N,N</i> -dimethylformamide |
|    | DMSO              | dimethylsulfoxide             |
| 20 | Et <sub>2</sub> O | diethyl ether                 |
|    | EtOAc             | ethyl acetate                 |
|    | MgSO <sub>4</sub> | magnesium sulfate             |
|    | NMP               | 1-methylpyrrolidin-2-one      |
|    | THF               | tetrahydrofuran               |
| 25 | H <sub>2</sub> O  | water                         |

**Example 1****3-[[2-amino-5-[[2-(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-propanoic acid**

5

**2-Amino-5-[[2-(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one**

To a solution of 3-bromo- propanoic acid (367 mg) in DMF (10 ml) was added 2-Amino-5-[[2-(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (see WO0009511) (250 mg), N,N-diisopropylethylamine (105 mg) and a catalytic amount of sodium iodide the mixture was then heated at 90°C-100°C for 2 days. The reaction mixture was then evaporated under reduced pressure before separating between ethyl acetate (200ml) and water (200ml). The aqueous phase was then re-extracted with ethyl acetate (2 x 200ml). The combined organics were then dried using MgSO<sub>4</sub>, filtered and evaporated to give a residue which was purified by reverse phase HPLC. Yield 36mg.


15 MS APCI(-ve) 379[M-H]<sup>-</sup>

<sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 7.65 - 7.61 (1H, m), 7.33 - 7.29 (1H, m), 7.14 - 7.09 (2H, m), 4.59 (2H, s), 4.34 (2H, t), 2.70 (2H, t)

20

25

30

**Example 2****3-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-propanamide**

5

To a solution of 3-chloro-propanamide (258 mg) in DMF (10 ml) was added 2-Amino-5-[[2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (see WO0009511) (250 mg), N,N-diisopropylethylamine (105 mg) and a catalytic amount of sodium iodide the mixture was then heated at 90°C-100°C for 2 days. The reaction mixture was then

10 evaporated under reduced pressure before separating between ethyl acetate (200ml) and water (200ml). The aqueous phase was then re-extracted with ethyl acetate (2 x 200ml). The combined organics were then dried using MgSO<sub>4</sub>, filtered and evaporated to give a residue which was purified by reverse phase HPLC. Yield 15mg.

15 MS APCI(+ve) 378[M-H]<sup>+</sup>

<sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 7.59 - 7.54 (1H, m), 7.29 - 7.24 (1H, m), 7.13 - 7.05 (2H, m), 4.72 (2H, t), 4.48 (2H, s), 2.68 (2H, t)


20

25

30

**Example 3**

***N*-[2-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]ethyl]- acetamide**




- 5 To a solution of *N*-(2-chloroethyl)-acetamide (292 mg) in DMF (10 ml) was added 2-Amino-5-[[2-(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (see WO0009511) (250 mg), *N,N*-diisopropylethylamine (105 mg) and a catalytic amount of sodium iodide the mixture was then heated at 90°C-100°C for 2 days. The reaction mixture was then evaporated under reduced pressure before separating between ethyl acetate
- 10 (200ml) and water (200ml). The aqueous phase was then re-extracted with ethyl acetate (2 x 200ml). The combined organics were then dried using MgSO<sub>4</sub>, filtered and evaporated to give a residue which was purified by reverse phase HPLC. Yield 11mg.

MS APCI(+ve) 394[M+H]<sup>+</sup>

- <sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 7.57 - 7.53 (1H, m), 7.29 - 7.23 (1H, m), 7.12 - 7.05 (2H, m), 4.53
- 15 (2H, t), 4.47 (2H, s), 3.54 (2H, t), 1.93 (3H, s)

**Example 4**

**1-propanol, 2-[[2-amino-5-[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, (2*R*)-**



20

A solution of propanoic acid, 2-[[2-amino-5-[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, ethyl ester, (2*R*)- (0.23g)

in tetrahydrofuran (8ml) at 0°C was treated dropwise with a 2M solution of lithium borohydride in tetrahydrofuran (0.23ml). The mixture was allowed to reach ambient temperature and further stirred for 48h. The mixture was quenched with 2M hydrochloric acid and partitioned with ethyl acetate. The organics collected, washed with brine and then dried with MgSO<sub>4</sub> and solvent evaporated and the crude residue purified by silica gel chromatography eluting with 5% methanol/dichloromethane and then trituration with isohexane to give the title compounds as a white solid. (71mg)

MS APCI(+ve) 413[M+H]<sup>+</sup>

<sup>1</sup>H NMR: (DMSO) δ 8.41(s, 2H), 7.5(s, 1H), 7.37(d, 1H), 7.07(d, 1H), 3.31(m, 1H), 4.88(t, 1H), 4.32(s, 2H), 3.82(s, 3H), 3.52(s, 2H), 1.24(d, 3H).

The propanoic acid, 2-[[2-amino-5-[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, ethyl ester, (2*R*)- used as starting material was prepared as follows:

**i) propanoic acid, 2-[[2-amino-5-[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, ethyl ester, (2*R*)-**


A solution of 2-Amino-5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7(4*H*)-one (see WO0009511) (0.71g), triphenyl phosphine (0.53g), (S)-ethyl lactate (0.25ml) in tetrahydrofuran (30ml) at 0°C was treated dropwise with diisopropylazidodicarboxylate (0.42ml). The mixture was allowed to reach ambient temperature and further stirred for 16h before additional triphenyl phosphine (0.26g) and diisopropylazidodicarboxylate (0.21ml) was added. The mixture was further stirred for 48h. The mixture was partitioned between ethyl acetate and water. The organics collected, washed with brine, dried (MgSO<sub>4</sub>) and solvent evaporated. The residue purified by silica gel chromatography to give the subtitle compound as a white solid. Yield: 0.23g

<sup>1</sup>H NMR: (DMSO) δ 8.54 (s, 2H), 7.46(m, 1H), 7.35(m, 1H), 7.07(d, 1H), 5.33(q, 1H), 4.27(q, 2H), 4.13(m, 2H), 3.82(s, 3H), 1.53(d, 3H), 1.18(t, 3H),



**Example 5**

**(2R)-2-((2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)oxy)propan-1-ol**



5 A solution of 7-((1*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine (0.20g) in methanol (3ml) was added to a SCX cartridge. DCM followed by methanol was eluted through the cartridge, (eluent discarded). The compound was eluted with 4M ammonia in methanol/DCM (1:9), the relevant fractions were concentrated *invacuo* to give a white solid which was washed  
10 with *iso*-hexane, ether and DCM. The compound was purified by column chromatography on silica gel using methanol/DCM (1:9) as eluent, to give the title compound as a white solid. Yield: 28mg

MS APCI(+ve) 385[M+H]<sup>+</sup>

<sup>1</sup>H NMR: (DMSO) δ 8.48 (s, 2H), 7.43 - 7.27 (m, 2H), 7.19 - 7.10 (m, 1H), 5.32 - 5.23 (m,  
15 1H), 4.88 (t, 1H), 4.45 (dd, 2H), 3.52 (t, 2H), 1.21 (d, 3H)

The 7-((1*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine used as starting material was prepared as follows:


20 **i) 7-((1*R*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine**

The subtitle compound was prepared according to the procedure outlined in example 4 step i) using 2-Amino-5-(2,3-difluoro-benzylsulfanyl)-6H-thiazolo[4,5-*d*]pyrimidin-7-one (0.51g), 1-(*tert*-Butyl-dimethyl-silanyloxy)-propan-2-ol-(*S*) (0.47g), triphenyl phosphine (0.73g), tetrahydrofuran (30ml) and diisopropylazidodicarboxylate (0.55ml), to give the  
25 subtitle compound as a white solid. Yield: 0.20g

MS APCI(+ve) 499[M+H]<sup>+</sup>

**Example 6**

**(2*S*)-2-((2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl)oxy)propan-1-ol**



- 5 To a solution of 7-((1*S*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine (40mg) in THF (5ml) was added TBAF (0.16ml). The mixture was stirred at ambient temperature for 3h. The mixture was partitioned between ethyl acetate and water. The organics collected, washed with brine, dried (MgSO<sub>4</sub>) and solvent evaporated. The residue was purified by silica gel chromatography using methanol/DCM (1:9) as eluent, then further purified by reverse phase HPLC (symmetry as the stationary phase and ammonium acetate/acetonitrile as the mobile phase) The mixture was then titrated with methanol and DCM to give the title compound as a white solid. Yield: 10mg

MS APCI(+ve) 385[M+H]<sup>+</sup>

- 15 <sup>1</sup>H NMR: (DMSO) δ8.48 (s, 2H), 7.42 - 7.28 (m, 2H), 7.19 - 7.11 (m, 1H), 5.32 - 5.22 (m, 1H), 4.45 (dd, 2H), 3.56 - 3.48 (m, 2H), 1.21 (d, 3H)

- The 7-((1*S*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine used as starting material was prepared as follows:

**i) 7-((1*S*)-2-[[*tert*-butyl(dimethyl)silyl]oxy]-1-methylethoxy)-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-2-amine**


- 25 The subtitle compound was prepared according to the procedure outlined in example 4 step i) using 2-Amino-5-(2,3-difluoro-benzylsulfanyl)-6H-thiazolo[4,5-*d*]pyrimidin-7-one (0.51g), 1-(*tert*-Butyl-dimethyl-silanyloxy)-propan-2-ol-(R) (0.47g), triphenyl phosphine

(0.73g), tetrahydrofuran (30ml) and diisopropylazidodicarboxylate (0.55ml), to give the subtitle compound as a white solid. Yield: 40mg

MS APCI(-ve) 497[M-H]<sup>-</sup>

## 5 Example 7

**5-[(2,3-difluorobenzyl)thio]-7-[(1*R*)-2-hydroxy-1-methylethoxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one**



10 A solution of lithium borohydride (165  $\mu$ L) in THF (2.0 M) was added dropwise to a stirred solution of ethyl (2*R*)-2-({5-[(2,3-difluorobenzyl)thio]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy)propanoate (the product of step vi) (70mg) in THF (10mL) at 5°C. The mixture was allowed to warm to room temperature and stirred for a further 18h. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl

15 solution (10mL) and extracted with EtOAc (3 x 10mL). Combined organic extracts were washed with a saturated solution of brine (10mL), dried (MgSO<sub>4</sub>) and evaporated to dryness *in vacuo*. This crude residue was purified by reverse phase HPLC using a gradient of 75:25 to 5:95 mixture of 0.2% aqueous ammonium acetate solution and acetonitrile as eluent to give the title compound as a white solid (22mg).

20 MS APCI(-ve) 384[M-H]<sup>-</sup>

<sup>1</sup>H NMR:  $\delta$  (DMSO-*d*<sub>6</sub>) 1.21 (3H, d), 3.52 (2H, d), 4.46 (2H, dd), 4.91 (1H, s), 5.29 (1H, q), 7.17 (1H, t), 7.45 - 7.29 (2H, m).

The intermediates for this compound were prepared as follows:

**i) 6-amino-2-[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinol**

Aqueous sodium hydroxide solution (46-48% w/w; 24mL) followed by H<sub>2</sub>O (40mL) was added to a stirred suspension of 4-amino-6-hydroxy-2-mercaptopyrimidine monohydrate (67.7g) in a mixture of water (920mL) and THF (300mL). The resulting hazy, pale yellow solution was cooled to 20 °C before adding 2,3-difluorobenzyl bromide (83.0g) uniformly over 25 mins, to yield a white precipitate. The mixture was stirred at ambient temperature for 3.5 h, the product collected and washed twice with a mixture of H<sub>2</sub>O (68mL) and THF (24mL), to afford the subtitle compound as a white solid (101.89g).  
<sup>1</sup>H NMR: δ (DMSO-d<sub>6</sub>) 4.39 (2H, s), 5.01 (1H, s), 6.58 (2H, br.s), 7.15 (1H, m), 7.34 (1H, m), 7.44 (1H, t), 11.45 (1H, br.s).

**ii) 7-amino-5-[(2,3-difluorophenyl)methyl]thio][1,3]oxathiol[5,4-*d*]pyrimidin-2-one**

Chlorocarbonylsulfenyl chloride (4.89g) was added over 7 mins, followed by THF (2mL), to a stirred suspension of 6-amino-2-[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinol (the product of step i) (9.58g) in THF (96mL). The reaction mixture was stirred for 40 mins and the resulting precipitate collected by filtration, washing twice with THF (19mL), to afford the subtitle compound as a pale yellow solid (11.31g).  
<sup>1</sup>H NMR: δ (DMSO-d<sub>6</sub>) 4.39 (2H, s), 5.82 (1H, br.s), 7.16 (1H, m), 7.34 (1H, m), 7.45 (1H, t), 7.89 (1H, br.s),

**iii) 7-chloro-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-2-(3*H*)-one**

*N,N*-diethylaniline (2.46g), followed by acetonitrile (5mL), and then phosphorus oxychloride (7.41g), followed by acetonitrile (5mL) was first added to a stirred suspension of 7-amino-5-[(2,3-difluorophenyl)methyl]thio][1,3]oxathiol[5,4-*d*]pyrimidin-2-one (the product of step ii) (5.03g) and benzyltrimethylammonium chloride (2.58g) in acetonitrile (25mL) at 50 °C. The reaction mixture was heated to reflux and maintained at this temperature for 36 h, before cooling to ambient temperature and adding to H<sub>2</sub>O (25mL) at 50 °C with stirring over 30 mins. An additional acetonitrile (5ml) rinse of the reaction vessel was added to the down-out mixture, before heating to 75 °C. and slowly cooling to 25 °C at <0.5 °C/min. The resulting mixture was held at 25 °C for 30 mins and then collected by filtration, washing four times with water (25mL), to afford the subtitle compound as an off-white solid (3.5g).

<sup>1</sup>H NMR: δ (DMSO-d<sub>6</sub>) 7.45 (1H, t), 7.38 (1H, m), 7.22 (1H, m), 4.50 (2H, s), 3.43 (1H, br.s).

**iv) 7-chloro-5-[(2,3-difluorobenzyl)thio]-3-(tetrahydro-2H-pyran-2-yl)[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one**

*Para*-toluenesulfonic acid (10mg), followed by 3,4-dihydro-2H-pyran (0.56mL) was added to a solution of 7-chloro-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2(3H)-one (the product of step iii) (1.67g) in toluene (15mL) and the mixture heated at 60°C and stirred at that temperature for 3h. The mixture was allowed to cool to room temperature, and toluene (10mL) and saturated aqueous sodium bicarbonate solution (30mL) were added and then further stirred for 1h. The layers were separated and the organic layer was washed with saturated brine solution (10mL), dried (MgSO<sub>4</sub>) and evaporated to dryness *in vacuo*. The resulting crude oil was dissolved into Et<sub>2</sub>O (20mL) and MeOH (few drops) and evaporated again to give a 'wet' solid. This material was triturated with Et<sub>2</sub>O and filtered to give the subtitle compound as a yellow solid (1.86g). <sup>1</sup>H NMR: δ (DMSO-d<sub>6</sub>) 1.50 (2H, m), 1.70 (2H, m), 1.90 (1H, m), 2.60 (1H, m), 3.60 (1H, m), 3.99(1H, d), 4.54 (2H, s), 5.59 (1H, m), 7.20-7.13 (1H, m), 7.44-7.31 (2H, m).

**v) ethyl (2R)-2-[[5-[(2,3-difluorobenzyl)thio]-2-oxo-3-(tetrahydro-2H-pyran-2-yl)-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-7-yl]oxy}propanoate**

Ethyl lactate (0.28mL), followed by sodium hydride (80mg) was added to a solution of 7-chloro-5-[(2,3-difluorobenzyl)thio]-3-(tetrahydro-2H-pyran-2-yl)[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one (the product of step iv) (0.43g) in THF (20mL). The resulting mixture was stirred under nitrogen at room temperature for 18h before quenching with saturated aqueous ammonium chloride solution (20mL). This was then extracted with EtOAc (3 x 20mL) and the combined organic extracts were washed with saturated brine solution (20mL), dried (MgSO<sub>4</sub>) and evaporated to dryness *in vacuo* to give the crude subtitle compound as a yellow oil (680mg).

<sup>1</sup>H NMR: δ (DMSO-d<sub>6</sub>) 1.56-1.11 (7H, m), 1.74-1.57 (2H, m), 1.95-1.86 (1H, m), 2.74-2.59 (1H, m), 3.64-3.55 (1H, m), 4.05-3.97(1H, m), 4.18-4.07 (3H, m), 4.55-4.41 (2H, m), 5.47-5.37 (1H, m), 5.59 (1H, dt), 7.17 (1H, dd), 7.44-7.28 (2H, m),

**vi) ethyl (2*R*)-2-({5-[(2,3-difluorobenzyl)thio]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy)propanoate**


A solution of ethyl (2*R*)-2-{{5-[(2,3-difluorobenzyl)thio]-2-oxo-3-(tetrahydro-2*H*-pyran-2-yl)-2,3-dihydro[1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy}propanoate (the product of step v) (511mg) in a mixture of acetonitrile (20mL), water (3.5mL), THF (3.0mL) and 1N aqueous HCl (2.0mL) was heated at 60°C for 1.5h. The mixture was allowed to cool to room temperature, was diluted with H<sub>2</sub>O (20mL) and then extracted with EtOAc (3 x 20mL). Combined organic extracts were washed with saturated brine solution (20mL), dried (MgSO<sub>4</sub>) and evaporated to dryness *in vacuo*. The resulting crude residue was purified by flash column chromatography on silica gel, eluting with EtOAc/isohexane (1:9 to 3:7 gradient) as eluent to afford the subtitle compound as a an oil (220mg).

MS APCI(+ve) 428[M+H]<sup>+</sup>

<sup>1</sup>H NMR: δ (DMSO-*d*<sub>6</sub>) 1.13 (3H, t), 1.53 (3H, d), 4.11(2H, ddd), 4.42 (2H, dd), 5.40 (1H, q), 7.21-7.13 (1H, m), 7.42-7.27 (2H, m), 13.10 (1H, s),

**CLAIMS**

1. A compound of general formula (I)



5

wherein

- $R^1$  is a group selected from  $C_{3-7}$ carbocyclyl,  $C_{1-8}$ alkyl,  $C_{2-6}$ alkenyl and  $C_{2-6}$ alkynyl; wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, nitrile,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ , phenyl or heteroaryl; wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_{1-6}$ alkyl and trifluoromethyl;

- $X$  is  $-CH_2-$ , a bond, oxygen, sulphur, sulphoxide, or sulphone;

- $Z$  is  $-CH_2-$ , a bond, oxygen, sulphur, sulphoxide, sulphone or  $-NR^5$ ;

$R^2$  is  $C_{3-7}$ carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently selected from: fluoro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ;

- or  $R^2$  is a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S,  $-NR^8$  and whereby the ring is optionally substituted by 1, 2 or 3 substituents independently selected from  $C_{1-3}$ alkyl, fluoro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-COOR^7$ ,  $-NR^8COR^9$ ,  $-SR^{10}$ ,  $-SO_2R^{10}$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ;

- or  $R^2$  is phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro,  $-OR^4$ ,  $-NR^5R^6$ ,  $-CONR^5R^6$ ,  $-NR^8COR^9$ ,  $-SO_2NR^5R^6$ ,  $-NR^8SO_2R^9$ ,  $C_{1-6}$ alkyl and trifluoromethyl;


or  $R^2$  is a group selected from  $C_{1-8}$ alkyl,  $C_{2-6}$ alkenyl or  $C_{2-6}$ alkynyl wherein the group is substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino,

C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub>alkyl)amino, *N*-(C<sub>1-6</sub>alkyl)-*N*-(phenyl)amino, *N*-C<sub>1-6</sub>alkylcarbamoyl, *N,N*-di(C<sub>1-6</sub>alkyl)carbamoyl, *N*-(C<sub>1-6</sub>alkyl)-*N*-(phenyl)carbamoyl, carboxy, phenoxycarbonyl, -NR<sup>8</sup>COR<sup>9</sup>, -SO<sub>2</sub>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup> and -CONR<sup>5</sup>R<sup>6</sup>;

5 Y is selected from hydrogen, hydroxyl, halo, -NR<sup>3</sup>R<sup>4</sup>, and -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup>;

R<sup>3</sup> and R<sup>4</sup> each independently represent a hydrogen atom, or a 4-piperidinyl group, or R<sup>3</sup> and R<sup>4</sup> each independently represent a C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>1</sub>-C<sub>8</sub> alkyl group, which groups may be optionally substituted by 1, 2 or 3 substituent groups independently -SO<sub>2</sub>R<sup>10</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup>, morpholinyl, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, 10 tetrahydrofuranyl and aryl, wherein an aryl group may be optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -NR<sup>5</sup>R<sup>6</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -OR<sup>7</sup>, -NR<sup>8</sup>COR<sup>9</sup>, -SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, -NR<sup>8</sup>SO<sub>2</sub>R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl and trifluoromethyl,

or R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system, which ring system may be optionally 15 substituted by one or more substituent groups independently selected from



20 -NR<sup>5</sup>R<sup>6</sup>, -CONR<sup>5</sup>R<sup>6</sup>, -OR<sup>7</sup>, -COOR<sup>10</sup>, -NR<sup>8</sup>COR<sup>9</sup>, and C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted by 1, 2 or 3 substituents independently selected from halogen atoms and -NR<sup>11</sup>R<sup>12</sup> and -OR<sup>7</sup> groups;

R<sup>5</sup> and R<sup>6</sup> are independently hydrogen or a group selected from C<sub>1-6</sub>alkyl and phenyl wherein the group is optionally substituted by 1, 2 or 3 substituents independently 25 selected from halo, phenyl, -OR<sup>14</sup>, -NR<sup>15</sup>R<sup>16</sup>, -COOR<sup>14</sup>, -CONR<sup>15</sup>R<sup>16</sup>, -NR<sup>15</sup>COR<sup>16</sup>, -SO<sub>2</sub>R<sup>10</sup>, -SONR<sup>15</sup>R<sup>16</sup> and NR<sup>15</sup>SO<sub>2</sub>R<sup>16</sup>

R<sup>7</sup> and R<sup>9</sup> each independently represent a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>, particularly C<sub>1</sub>-C<sub>4</sub>, alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group, each of



which may be optionally substituted by one or more (e.g. one, two, three or four) substituent groups independently selected from halogen atoms (e.g. fluorine, chlorine, bromine or iodine), phenyl,  $-OR^{17}$  and  $-NR^{15}R^{16}$ ; and

each of  $R^8$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{15}$ ,  $R^{16}$  and  $R^{17}$  independently represents a hydrogen

- 5 atom or a  $C_1$ - $C_6$ , particularly  $C_1$ - $C_4$ , alkyl (e.g. methyl, ethyl, propyl, butyl, pentyl or hexyl) or phenyl group  
or a pharmaceutically acceptable salt or solvate thereof.

2. A compound or a pharmaceutically acceptable salt or solvate thereof as claimed in  
10 claim 1 wherein  $R^1$  is a  $C_{1-4}$  alkyl group optionally substituted by a phenyl or heteroaryl group optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl.

3. A compound or a pharmaceutically acceptable salt or solvate thereof as claimed in  
15 claim 1 wherein X is a bond,  $-CH_2-$ , oxygen, or sulphur.

4. A compound or a pharmaceutically acceptable salt or solvate thereof as claimed in  
claim 1 wherein  $R^2$  is  $C_{1-4}$ alkyl substituted with 1 or 2 hydroxy groups, carboxy,  $-NHCOC_{1-4}$ alkyl or  $-CONR^5R^6$  wherein  $R^5$  and  $R^6$  are either hydrogen or  $C_{1-4}$ alkyl.

20

5. A compound or a pharmaceutically acceptable salt or solvate thereof as claimed in  
claim 1 wherein Y is hydroxyl,  $-NR^3R^4$  or  $-NR^8SO_2R^9$  wherein  $R^3$ ,  $R^4$ ,  $R^8$  are either  
hydrogen or  $C_{1-4}$ alkyl and  $R^9$  is either  $C_{1-4}$ alkyl or trifluoromethyl.

- 25 6. A compound or a pharmaceutically acceptable salt or solvate thereof as claimed in  
claim 1 wherein Z is a bond or sulphur.

7. A compound selected from the group consisting of:

3-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-

- 30 propanoic acid,

3-[[2-amino-5-[[2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-propanamide,

*N*-[2-[[2-amino-5-[[2-fluorophenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]ethyl]-acetamide,

5 1-propanol, 2-[[2-amino-5-[[3-chloro-4-methoxyphenyl)methyl]thio]thiazolo[4,5-*d*]pyrimidin-7-yl]oxy]-, (2*R*)-,

(2*R*)-2-({2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-yl}oxy)propan-1-ol, and

(2*S*)-2-({2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-*d*]pyrimidin-7-

10 yl}oxy)propan-1-ol

5-[(2,3-difluorobenzyl)thio]-7-[(1*R*)-2-hydroxy-1-methylethoxy][1,3]thiazolo[4,5-*d*]pyrimidin-2(3*H*)-one

or a pharmaceutically acceptable salt or solvate thereof

15 8. A compound, or a pharmaceutically acceptable salt, or solvate thereof according to any one of claims 1 to 7 for use as a medicament.

9. A compound, or a pharmaceutically acceptable salt, or solvate thereof according to any one of claims 1-7 for use as a medicament for the treatment of asthma, allergic rhinitis,  
20 COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis..

10. A compound, or a pharmaceutically acceptable salt, or solvate thereof according to any one of claims 1-7, for use as a medicament for the treatment of cancer.

25

11. The use of a compound, or a pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1-7 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

30

12. The use of a compound, or a pharmaceutically acceptable salt, or solvate thereof, according to any one of claims 1-7 in the manufacture of a medicament for the treatment of


asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

13. The use of a compound, or a pharmaceutically acceptable salt, or solvate thereof,  
5 according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of cancer.

14. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, or solvate thereof according to any one of claims 1-7; and a  
10 pharmaceutically-acceptable diluent or carrier.


15. A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt, or solvate thereof, which comprises the steps of:

(i) reacting a compound of general formula (III); wherein L is a leaving group and  
15 PG is a suitable protecting group



with a suitable nucleophile in the presence or absence of a suitable base and solvent

(ii) when X represents -O- or -S-, and R¹, Z and Y are as defined in formula (I), with the proviso that Y is not hydroxyl, reacting a compound of general formula (II)



20 with a suitable alkylhalide (R²-L) wherein R² is as defined in formula (I) and L is a leaving group under Mitsunobu reaction conditions using a trialkyl- or triaryl- phosphine and dialkylazidodicarboxylate in the presence of a suitable base and solvent; or

(iii) for compounds of formula (I), wherein X and/or Z are sulphoxide or sulphone and R<sup>1</sup> and R<sup>2</sup> are as defined hereinbefore, by further reaction of compounds of formula (I), wherein X and/or Z are sulphur, with a suitable oxidising reagent;

and optionally thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in any order:

- 5 i) removing any protecting groups;  
ii) converting the compound of formula (I) into a further compound of formula (I)  
iii) forming a salt.

16. A combination therapy which comprises administering a compound of formula (I)  
10 or a pharmaceutically acceptable salt, or solvate thereof, or a pharmaceutical composition or formulation comprising a compound of formula (I), concurrently or sequentially with other therapy and/or another pharmaceutical agent.

17. A combination therapy as claimed in claim 16 for the treatment of asthma, allergic  
15 rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

18. A combination therapy as claimed in claim 16 for the treatment of cancer.

20 19. A pharmaceutical composition which comprises a compound of formula (1) or a pharmaceutically acceptable salt, or solvate thereof, in conjunction with another pharmaceutical agent.

20. A pharmaceutical composition as claimed in claim 19 for the treatment of asthma,  
25 allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.

21. A pharmaceutical composition as claimed in claim 19 for the treatment of cancer.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number  
**WO 2006/064228 A3**

(51) International Patent Classification:  
**C07D 513/04** (2006.01) **A61P 29/02** (2006.01)  
**A61K 31/519** (2006.01)

& D Charnwood, Bakewell Road, Loughborough Leices-  
tershire LE11 5RH (GB).

(21) International Application Number:  
PCT/GB2005/004825

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-  
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date:  
14 December 2005 (14.12.2005)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,  
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0427698.6 17 December 2004 (17.12.2004) GB  
0502542.4 8 February 2005 (08.02.2005) GB

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except MG, US*): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (*for MG only*): ASTRAZENECA UK LIM-  
ITED [GB/GB]; 15 Stanhope Gate, London, Greater Lon-  
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MEGHANI, Pre-  
mji [GB/GB]; AstraZeneca R & D Charnwood, Bakewell  
Road, Loughborough Leicestershire LE11 5RH (GB).  
CHESHIRE, David, Ranulf [GB/GB]; AstraZeneca R  
& D Charnwood, Bakewell Road, Loughborough Leices-  
tershire LE11 5RH (GB). PRESTON, Cherylin, Francis  
[GB/GB]; AstraZeneca R & D Charnwood, Bakewell  
Road, Loughborough Leicestershire LE11 5RH (GB).  
STONEHOUSE, Jeffrey, Paul [GB/GB]; AstraZeneca R


Published:

— with international search report

(88) Date of publication of the international search report:  
8 February 2007

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: THIAZOLOPYRAMIDINE COMPOUNDS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY



(57) Abstract: A compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof; and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

WO 2006/064228 A3

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2005/004825

## A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D513/04 A61K31/519 A61P29/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| P,X       | BAXTER, ANDREW ET AL: "Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists" BIOORG. MED. CHEM. LETT. , 16(4), 960-963 CODEN: BMCLE8; ISSN: 0960-894X, 2006, XP002374953 the whole document | 1-6,<br>8-10,15       |
| Y         | WO 00/09511 A (ASTRA PHARMACEUTICALS LTD; ASTRA AKTIEBOLAG; AUSTIN, RUPERT; BAXTER, A) 24 February 2000 (2000-02-24) cited in the application the whole document   | 1-21                  |

-/--



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 October 2006

Date of mailing of the international search report

26/10/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Zellner, Armin

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2005/004825

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |   |                       |
|--|---|-----------------------|
| Category*  | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
| P,Y  | WO 2005/033115 A (ASTRAZENECA AB;<br>NORDVALL, GUNNAR; REIN, TOBIAS; SOHN,<br>DANIEL; ZEMRIBO.)<br>14 April 2005 (2005-04-14)<br>the whole document<br>-----    | 1-25                  |
| P,Y  | WO 2005/082865 A (YAMANOUCHI<br>PHARMACEUTICAL CO., LTD; KAWANO, NORIYUKI;<br>IGARASHI, SUSUMU)<br>9 September 2005 (2005-09-09)<br>the whole document<br>----- | 1-25                  |
| Y  | EP 1 348 709 A (ASTRAZENECA UK LIMITED)<br>1 October 2003 (2003-10-01)<br>the whole document<br>-----   | 1-21                  |
| Y  | WO 01/58906 A (ASTRAZENECA AB; BONNERT,<br>ROGER; HUNT, FRASER; WILLIS, PAUL)<br>16 August 2001 (2001-08-16)<br>the whole document<br>-----                     | 1-21                  |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2005/004825

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 16-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6,8-21

Compounds of general formula (I) wherein X is -CH<sub>2</sub>- and the subject-matter of claims 2-6, 8-21 relating to these compounds.

---

2. claims: 1-6,8-21

Compounds of general formula (I) wherein X is a bond and the subject-matter of claims 2-6, 8-21 relating to these compounds.

---

3. claims: 1-21

Compounds of general formula (I) wherein X is oxygen and the subject-matter of claims 2-21 relating to these compounds.

---

4. claims: 1-6,8-21

Compounds of general formula (I) wherein X is sulphur, sulfoxide, sulphone and the subject-matter of claims 2-6, 8-21 relating to these compounds.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2005/004825

| Patent document<br>cited in search report |   | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---|---------------------|----------------------------|---------------------|
| WO 0009511                                | A | 24-02-2000          | AT 231872 T                | 15-02-2003          |
|   |   |                     | AU 768004 B2               | 27-11-2003          |
|   |   |                     | AU 5662599 A               | 06-03-2000          |
|   |   |                     | CA 2338600 A1              | 24-02-2000          |
|   |   |                     | DE 69905170 D1             | 06-03-2003          |
|   |   |                     | DE 69905170 T2             | 15-01-2004          |
|   |   |                     | DK 1104425 T3              | 23-06-2003          |
|   |   |                     | EP 1104425 A1              | 06-06-2001          |
|   |   |                     | ES 2190246 T3              | 16-07-2003          |
|   |   |                     | JP 2002522544 T            | 23-07-2002          |
|   |   |                     | NZ 509457 A                | 26-07-2002          |
|   |   |                     | US 6806273 B1              | 19-10-2004          |
| WO 2005033115                             | A | 14-04-2005          | AU 2004278276 A1           | 14-04-2005          |
|   |   |                     | CA 2541533 A1              | 14-04-2005          |
|   |   |                     | EP 1675862 A1              | 05-07-2006          |
|   |   |                     | MX PA06003792 A            | 14-06-2006          |
| WO 2005082865                             | A | 09-09-2005          | NONE                       |                     |
| EP 1348709                                | A | 01-10-2003          | SI 1222195 T1              | 30-06-2004          |
| WO 0158906                                | A | 16-08-2001          | AT 255584 T                | 15-12-2003          |
|   |   |                     | AU 3255601 A               | 20-08-2001          |
|   |   |                     | DE 60101372 D1             | 15-01-2004          |
|   |   |                     | DE 60101372 T2             | 14-10-2004          |
|   |   |                     | EP 1257555 A1              | 20-11-2002          |
|   |   |                     | JP 2003522191 T            | 22-07-2003          |